A number of studies support the association of CD166/ALCAM expression with aggressiveness in a variety of cancers, including melanoma, prostate, breast, ovarian, esophageal, bladder and intestinal cancers (probably a result of homophilic ALCAM-ALCAM interactions), thus constituting of an oncology-related target and prognostic marker [107,108]. This evidence concerns the gene ALCAM and melanoma.